The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS
NIL
Jahr
Publikationsjahr
2019
Autoren
Autorenliste der Publikation
Akgün K, Kretschmann N, Haase R, Proschmann U, Kitzler HH, Reichmann H, Ziemssen T.
Verlag
Publisher-Information
Neurol Neuroimmunol Neuroinflamm. 2019 Apr 8;6(3):e555.
Link
Zur Publikation (externer Server)
https://doi.org/10.1212/nxi.0000000000000555
Tags
Forschungsthemen
Neuroimmunologie
NIL
2019
Serum neurofilament light chain as a sensitive biomarker for neuromonitoring during extracorporeal membrane oxygenation
NIL
Jahr
2024
Raman Spectroscopy of Optically Trapped Living Human T Cell Subsets and Monocytes
NIL
Jahr
2024
COVID-19 and multiple sclerosis: challenges and lessons for patient care
Multiple Sclerosis
Jahr
2024
Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374
NIL
Jahr
2024
SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma
NIL
Jahr
2024